Brokerages expect Mersana Therapeutics Inc (NASDAQ:MRSN) to post earnings per share (EPS) of ($0.38) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mersana Therapeutics’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.36). Mersana Therapeutics reported earnings per share of ($0.36) during the same quarter last year, which indicates a negative year over year growth rate of 5.6%. The firm is scheduled to announce its next earnings results on Thursday, August 13th.

On average, analysts expect that Mersana Therapeutics will report full-year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.07). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.16) per share, with EPS estimates ranging from ($1.33) to ($0.90). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.37 million. Mersana Therapeutics had a negative return on equity of 78.18% and a negative net margin of 6,099.64%.

MRSN has been the topic of a number of research analyst reports. ValuEngine raised Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. BTIG Research increased their target price on Mersana Therapeutics from $21.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, June 24th. Robert W. Baird increased their target price on Mersana Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, May 28th. SVB Leerink increased their target price on Mersana Therapeutics from $12.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Finally, BidaskClub raised Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Eight investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $21.10.

Shares of NASDAQ:MRSN traded up $1.12 during midday trading on Thursday, reaching $23.40. 1,929,208 shares of the company’s stock traded hands, compared to its average volume of 1,426,101. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -16.71 and a beta of 2.79. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.59 and a current ratio of 4.59. Mersana Therapeutics has a one year low of $1.32 and a one year high of $24.07. The stock has a 50 day moving average of $17.06 and a 200 day moving average of $9.52.

In related news, Director Andrew A. F. Hack acquired 3,445,667 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were purchased at an average price of $9.43 per share, with a total value of $32,492,639.81. Following the completion of the purchase, the director now directly owns 538,599 shares of the company’s stock, valued at $5,078,988.57. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Scott D. Sandell sold 20,914 shares of the stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $8.50, for a total value of $177,769.00. The disclosure for this sale can be found here. 5.30% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in MRSN. Marshall Wace LLP purchased a new stake in shares of Mersana Therapeutics during the first quarter worth about $141,000. California Public Employees Retirement System purchased a new stake in shares of Mersana Therapeutics during the fourth quarter worth about $147,000. Rhumbline Advisers grew its position in shares of Mersana Therapeutics by 5.6% during the fourth quarter. Rhumbline Advisers now owns 46,351 shares of the company’s stock worth $266,000 after purchasing an additional 2,448 shares in the last quarter. State Street Corp grew its position in shares of Mersana Therapeutics by 3.5% during the fourth quarter. State Street Corp now owns 620,685 shares of the company’s stock worth $3,557,000 after purchasing an additional 21,025 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Mersana Therapeutics by 27.6% during the 4th quarter. Acadian Asset Management LLC now owns 129,596 shares of the company’s stock valued at $742,000 after buying an additional 28,001 shares in the last quarter. Hedge funds and other institutional investors own 72.28% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Recommended Story: What is the definition of market timing?

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.